Innospark Ventures

Innospark Ventures Research Investment Thesis Innospark Ventures is a specialized AI venture capital firm founded on the principle that "expertise unlocks AI's full potential." The firm invests exclusively in early-stage companies where artificial intelligence is paired with deep domain expertise to solve intractable problems. Founded by Dr. Venkat Srinivasan, a serial entrepreneur with multiple AI-driven exits, Innospark believes that meaningful innovation comes from technical founders who harness industry expertise, apply novel AI applications, and push the boundaries of what's possible. The firm's core belief is that transformative breakthroughs require pairing AI with deep domain knowledge. They seek technical founders with engineering excellence and domain mastery who can redefine industries through AI-driven solutions. Innospark operates as more than a capital provider—they are operators and strategists who guide founders from idea to impact. Investment Focus Areas Innospark invests across three primary verticals where AI can drive foundational change: Healthcare AI: Leveraging AI to revolutionize healthcare with personalized care, seamless access, and equitable solutions that align patients, providers, and payors. Portfolio companies like Fourier Health, CredaHealth, and Dyania Health exemplify this focus. Life Sciences AI: Using AI to drive breakthroughs in drug discovery, development, and delivery. The firm backs companies applying computational biology, machine learning, and high-throughput automation to accelerate life sciences innovation. Notable investments include Antiverse, Arrepath, BioIntelligence, and Encora. Enterprise AI: Supporting companies transforming enterprise operations through AI, unlocking scale, efficiency, and innovation. Investments span from observability and monitoring (Deeplite, Entromy) to specialized applications like English Helper and robotics platforms (Ava Robotics). Stage and Check Size Innospark primarily focuses on pre-seed and seed stage investments . Based on portfolio analysis: Seed Stage: Primary focus, $1M-$5M typical investment Pre-Seed: Secondary focus for exceptional technical founders, $500K-$1.5M Series A: Selective follow-on investments for portfolio companies demonstrating strong progress The fund appears to maintain reserve capital for follow-on investments and has been actively deploying recent years. Lead Tendency Based on portfolio composition and team size, Innospark appears to lead or co-lead rounds at the seed stage. The team structure with multiple partners and principals allows them to manage a diversified portfolio while maintaining deep engagement with portfolio companies. Recent Activity and Fund Status Innospark has been actively deploying capital through 2025 and into 2026. Recent notable investments include: Q4 2025: Fourier Health Series A (medical records/AI summarization) Q4 2025: Via Scientific seed round ($5M, led by G20 Ventures with Innospark participation) Q3 2025: Persist AI Series A (drug discovery automation) Q2 2025: Dyania Health (clinical trial automation) CB Insights reports 66 total investments in the firm's portfolio. The firm was founded in 2019 and has maintained consistent activity through the venture cycle. As of February 2026, the firm continues to make investments, indicating active fund deployment. Portfolio Composition The portfolio spans 40+ known companies across healthcare, life sciences, and enterprise sectors. Portfolio characteristics: Heavy focus on applied AI: Every portfolio company has AI as core technology Deep domain expertise founders: Many founders have PhD/MD backgrounds or significant industry experience Geographic concentration: Strong Boston/East Coast presence reflecting the firm's location and MIT/Harvard sourcing ties Sector distribution: ~40% Healthcare, ~30% Life Sciences, ~30% Enterprise Portfolio companies include (sampled): Adeptmind, Airworks, Antiverse, Arrepath, Ava Robotics, BioIntelligence, Clairways, Copernic Catalysts, CredaHealth, Deeplite, Dyania Health, Encora, English Helper, Entri, Entromy, Fourier Health, and many others across multiple exits and valuations. Team and Operating Model Innospark operates with a lean but highly experienced team combining AI expertise with domain-specific knowledge: Leadership: Dr. Venkat Srinivasan, Founder & Managing Director: Serial entrepreneur with multiple AI-driven exits (eCredit acquired by ICG, Rage Frameworks acquired by Genpact). Deep expertise in computational linguistics, finance, and accounting. Author of "The Intelligent Enterprise in the Era of Big Data." Holds 8 patents and published 30+ peer-reviewed papers. Deepak Verma, Operating Partner: Brings diverse entrepreneurial and operating experience. Previously CEO of eCredit, consultant at McKinsey, founder of solar power company (acquired 2018), and served as CEO of Clinton Foundation's HIV/AIDS Initiative (CHAI). Deep expertise in strategy, commercialization, and organizational effectiveness. Matt Fates, Partner: Technology investor with 25+ years experience. Invested in 100+ companies across data analytics, SaaS, and cybersecurity. Prior roles at Ascent Venture Partners (2002-2021) and Norwest Venture Partners (1998-2000). Yale CS graduate, Tuck MBA. Investment Team: Brent Willess, Principal: Former investor at Founder Collective (backed Suno, Motorway), early employee at Uber. Virginia Tech Finance, Yale MBA. Mark Legare, Principal: With Innospark since founding. Former Senior Special Assistant to MA Governor Charlie Baker. Focus on digital health and tech-enabled services. Holy Cross graduate. Jeff Knox, Senior Associate: Focused on computational intelligence applications in biotech. Consultant to biopharma/digital health companies. Managing Director of Boston Nucleate chapter. Johns Hopkins BME, MIT Sloan MBA. Operations & Support: Lily Zarrella, Senior Director of Operations & Platform: Manages operational functions, network development, and portfolio support. Former Deputy Chief of Staff to MA Governor Baker. Boston University graduate. Max Krause, Senior Analyst & Head of Founder Discovery: Leads sourcing strategy and founder discovery across verticals. Holy Cross graduate. Marjan Majid, Analyst: Supports deal sourcing and diligence in healthcare/life sciences/tech. UT Austin BME, Rice M.S. Bioengineering. Technologists in Residence: The firm maintains a cadre of advanced-degree technologists from leading institutions: Yuri Ahuja: Physician at NYU Langone, CTO at Oatmeal Health. Yale BS, Harvard MD/PhD. Focus on ML applications in healthcare. Kevin Dunnell: PhD student at MIT Media Lab. Prior roles at Fiat Chrysler, Infosys, Vianai. 5 patents in AI optimization. U Michigan Aerospace, MIT Media Arts & Science. This structure gives Innospark deep technical diligence capability, operational support for founders, and strong connections to academic and research institutions. Decision Process and Timeline Based on team structure and firm profile: Decision Process: Partnership/committee with principals and operating partners Decision Timeline: Estimated 2-4 weeks for seed decisions, longer for complex biotech/life sciences Warm Introductions: Important given the firm's emphasis on sourcing through trusted networks and institutional connections Founder and Company Preferences Founder Profile: Innospark explicitly seeks technical founders with deep domain expertise . The ideal founder combines: Advanced degrees (PhD/MD common in life sciences, CS/engineering in enterprise) Industry experience or academic research background Track record of shipping products or research contributions Ability to apply AI as a force multiplier in their domain Anti-thesis: The firm is clear in avoiding generalist AI companies without domain differentiation, pure software plays without meaningful AI innovation, and companies that treat AI as an afterthought rather than core technology. Sourcing and Network Innospark has strong sourcing advantages: Academic Ties: Deep connections to MIT and Harvard research communities through the founding team and technologist network East Coast Network: Strong relationships across Boston, New York, and Cambridge innovation ecosystems Operator Network: Connections through prior entrepreneurial ventures and operating roles Industry Connections: Relationships developed through advisor network and portfolio company networks Go-to-Market Approach The firm supports founders through the journey from idea to impact by providing: AI Acumen: Deep technical knowledge of AI applications and implementation Operational Insight: Extensive experience scaling startups across geographies and stages Strategic Guidance: Hands-on support on strategy, commercialization, and market expansion Network Access: Connections to industry partners, customers, and follow-on investors Recent Market Context Innospark is well-positioned within the broader AI venture landscape. According to recent industry data, approximately 50% of global venture funding in 2025 went to AI-related companies, with AI funding reaching $211 billion (up 85% YoY from 2024). The firm's focus on applied AI with domain expertise positions it well as the market matures beyond general-purpose AI tools. Confidence Assessment This research is based on: Comprehensive website analysis (homepage, portfolio, team, strategy) Detailed team biographies and backgrounds Portfolio company verification across 40+ investments Recent news and funding activity verification Cross-reference with CB Insights and PitchBook data High confidence in thesis, team composition, and investment stage preferences. Confidence lower on specific AUM (not disclosed publicly) and exact fund sizing, which are typical privately held information for venture firms.